Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Mebias Discovery
AddedFeb 16, 2024
UpdatedJun 18, 2026
Mebias Discovery

Mebias Discovery

Mebias Discovery: Pioneering platform for next-gen GPCR drug discovery.

HQ
Philadelphia, PA, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Mebias Discovery is dedicated to revolutionizing drug discovery through its pioneering platform focused on G-protein coupled receptor (GPCR) targets. Utilizing a proprietary membrane protein-NMR drug discovery platform, Mebias identifies molecules that bind to GPCR targets, aiming to eliminate on-target adverse effects and enhance the therapeutic index. The company is committed to advancing and partnering its wholly owned molecules, driving innovation in the pharmaceutical industry.

Mebias Discovery has made significant strides in the field of GPCR drug discovery, leveraging its advanced technology to create novel therapeutic solutions. Its impact is underscored by the development of molecules with improved safety profiles and efficacy, addressing critical needs in medical treatments. By pushing the boundaries of traditional drug discovery methods, Mebias is poised to make substantial contributions to healthcare and pharmaceutical advancements.

Mebias Discovery - Similar Companies

Seven Biosciences logo

Seven Biosciences

Septerna logo

Septerna

septerna.com

Abilita Bio logo

Abilita Bio

abilitabio.com

Melior Discovery logo

Melior Discovery

Harmonic Discovery logo

Harmonic Discovery

Design Pharmaceuticals logo

Design Pharmaceuticals

Belharra Therapeutics logo

Belharra Therapeutics

ZielBio logo

ZielBio

zielbio.com

Triana Biomedicines logo

Triana Biomedicines

trianabio.com

Ribometrix logo

Ribometrix

ribometrix.com

Unravel Biosciences logo

Unravel Biosciences

unravel.bio

Ventus Therapeutics logo

Ventus Therapeutics

Biosortia Microbiomics logo

Biosortia Microbiomics

biosortia.com

Atommap logo

Atommap

Cipherome logo

Cipherome

cipherome.com

Mebias Discovery - Quick Facts

Who are Mebias Discovery's competitors?

Companies similar to Mebias Discovery include Seven Biosciences, Septerna, Abilita Bio and Melior Discovery.

When was Mebias Discovery founded?

Mebias Discovery was founded in 2015.

Where is Mebias Discovery's headquarters located?

Mebias Discovery's headquarters is located in Philadelphia, PA, US.

When was Mebias Discovery's last funding round?

Mebias Discovery's most recent funding round was for $630.7k (USD) in September 2022.

How much has Mebias Discovery raised to-date?

As of Sep 23, 2022, Mebias Discovery has raised a total of $4.1M (USD).

How many employees does Mebias Discovery have?

Mebias Discovery has 5 employees as of Feb 5, 2024.

Mebias Discovery - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Licensing
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • Biotech
  • Healthtech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software